BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9496389)

  • 1. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
    van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB
    Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group.
    Guastalla JP; Vermorken JB; Wils JA; George M; Scotto V; Nooij M; ten Bokkel Huinnink WW; Dalesio O; Renard J
    Eur J Cancer; 1994; 30A(1):45-9. PubMed ID: 8142163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer.
    de Jong RS; Willemse PH; Boonstra H; de Vries EG; van der Graaf WT; Sleijfer DT; van der Zee AG; Mulder NH
    Eur J Cancer; 1995; 31A(5):709-13. PubMed ID: 7640042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
    Willemse PH; Sleijfer DT; de Vries EG; Boonstra H; Bouma J; Mulder NH
    Eur J Cancer; 1992; 28(2-3):479-81. PubMed ID: 1591067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
    Malmström H; Rasmussen S; Simonsen E
    Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
    Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
    J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
    Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
    Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
    Kirmani S; Lucas WE; Kim S; Goel R; McVey L; Morris J; Howell SB
    J Clin Oncol; 1991 Apr; 9(4):649-57. PubMed ID: 2066761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.
    Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F
    Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
    Markman M; Blessing JA; Major F; Manetta A
    Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
    Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
    Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer.
    Morgan RD; Clamp AR; Hasan J; Mitchell C; Saunders G; Mescallado N; Welch R; Jayson GC
    Int J Gynecol Cancer; 2018 Mar; 28(3):448-452. PubMed ID: 29466253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.